UPDATE: UBS Upgrades Cepheid (CPHD) to Buy; Recent Dip Offers Opportunity
Tweet
Share
E-mailGet Alerts CPHD Hot Sheet
Price: $52.95 --0%
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - May 15, 2012 10:59 AM EDT)
UBS upgraded Cepheid (NASDAQ: CPHD) from Neutral to Buy. PT raised $1 to $45.
Analyst, Daniel Arias, said, "We are upgrading CPHD as a ~16% decline in shares since 3/26 (vs. ~5% for the S&P) has yielded an attractive buying opportunity, in our view. Overall business momentum appears solid, new product launches represent catalysts in 2H, and we view the company’s profile (no exposure to NIH budgeting, relatively low sensitivity to EU macro issues) as favorable. While shares remain at a premium (EV/ ’12 sales of 6.8x vs. 3.8x for CPHD’s diagnostics peers), we believe valuation is backed by a robust growth forecast & M&A potential."
UBS raises FY12 EPS from $0.16 to $0.18 and FY13 from $0.46 to $0.50.
For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $37.24 yesterday.
UBS upgraded Cepheid (NASDAQ: CPHD) from Neutral to Buy. PT raised $1 to $45.
Analyst, Daniel Arias, said, "We are upgrading CPHD as a ~16% decline in shares since 3/26 (vs. ~5% for the S&P) has yielded an attractive buying opportunity, in our view. Overall business momentum appears solid, new product launches represent catalysts in 2H, and we view the company’s profile (no exposure to NIH budgeting, relatively low sensitivity to EU macro issues) as favorable. While shares remain at a premium (EV/ ’12 sales of 6.8x vs. 3.8x for CPHD’s diagnostics peers), we believe valuation is backed by a robust growth forecast & M&A potential."
UBS raises FY12 EPS from $0.16 to $0.18 and FY13 from $0.46 to $0.50.
For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $37.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- KP Tissue Inc. (KPT:CN) (KPTSF) PT Raised to Cdn$13.50 at Desjardins
- Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, UpgradesRelated Entities
UBS, Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
